<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01507727</url>
  </required_header>
  <id_info>
    <org_study_id>HENGRUI20111231</org_study_id>
    <nct_id>NCT01507727</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled (Standard Therapy + Placebo) Study to Evaluate the Efficacy and Safety of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This drug has been developed to treat Hyponatremia. The primary purpose of this study is to
      verify the efficacy and safety of seven-day repeated oral administration of tolvaptan at 15,
      30, and 60 mg or placebo in patients with Non-hypovolemic Non-acute Hyponatremia secondary to
      Congestive Heart Failure (CHF), hepatic cirrhosis or Syndrome of Inappropriate Antidiuretic
      Hormone (SIADH), despite receiving standard therapy. This study is being conducted in China.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of average daily Area Under the Curve (AUC) of serum sodium by day 4 and 7 comparing with baseline serum sodium level within the double-blind therapy period</measure>
    <time_frame>4 and 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with normalized serum sodium at Day 4</measure>
    <time_frame>4 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with normalized serum sodium at Day 7</measure>
    <time_frame>7 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first normalization in serum sodium</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum sodium at Day 4</measure>
    <time_frame>4 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum sodium at Day 7</measure>
    <time_frame>7 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients requiring fluid restriction at any time during the double-blind therapy period of the study</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour urine output</measure>
    <time_frame>day 1, day 2, day 3, day 4, day 5, day 6 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight (hypervolemic patients only)</measure>
    <time_frame>day 1, day 2, day 3, day 4, day 5, day 6 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid balance (hypervolemic patients only)</measure>
    <time_frame>day 1, day 2, day 3, day 4, day 5, day 6 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients who are designated as treatment failure due to the need for saline infusion, with or without fluid restriction</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For CHF patients, improvement of symptoms and relevant physical examination measures</measure>
    <time_frame>day 1, day 2, day 3, day 4, day 5, day 6 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For hepatic edema patients, improvement of symptoms and relevant physical examination measures or ultrasound test findings</measure>
    <time_frame>day 1, day 2, day 3, day 4, day 5, day 6 and day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Non-hypovolemic Non-acute Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Drug: Tolvaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>Tablet;15mg/tab; 30mg/tab; 15/30/60mg/day for 7 days Plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.</description>
    <arm_group_label>Drug: Tolvaptan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.</description>
    <arm_group_label>Drug: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (for CHF):

          1. Patients with CHF who exhibit edema, jugular venous distention, hepatomegaly, or
             pulmonary congestion.

          2. Non-hypovolemic and Non-acute hyponatremia with a serum sodium &lt; 135mEq/L before
             randomization.

          3. Patients who have taken furosemide at 40 mg/d or more (oral dosing) without alteration
             of dosage for the 3 days of the observation period.

          4. Patients whose body weight has been stable (±1.0 kg) for 2 days prior to commencement
             of study drug administration.

          5. Age:18～80 (when informed consent is obtained)，male or female.

          6. In-patient subjects.

          7. Informed consent.

        Inclusion Criteria (for hepatic cirrhosis):

          1. Patients with hepatic edema.

          2. Non-hypovolemic and non acute hyponatremia with a serum sodium &lt; 135mEq/L before
             randomization.

          3. Age:18～65 (when informed consent is obtained)，male or female.

          4. In-patient subjects.

          5. Informed consent.

        Inclusion Criteria (for SIADH and others):

          1. Patients with SIADH arising from a variety of etiologies.

          2. Non-hypovolemic and non acute hyponatremia with a serum sodium &lt; 135mEq/L before
             randomization.

          3. Age:18～80 (when informed consent is obtained)，male or female.

          4. In-patient subjects.

          5. Informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fusheng Wang, PhD</last_name>
    <email>fswang@public.bta.net.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lin Zhu</last_name>
    <phone>051885475957</phone>
    <email>acetone_zhulin@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiology, Beijing An Zhen Hospital Affiliated to Capital University of Medical Science</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suo</last_name>
      <phone>010-64456464</phone>
    </contact>
    <investigator>
      <last_name>Changsheng Ma, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrinology, Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu</last_name>
      <phone>010-84205645</phone>
    </contact>
    <investigator>
      <last_name>Wenying Yang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hepatology, No. 302 Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu</last_name>
      <phone>010-63879892</phone>
    </contact>
    <investigator>
      <last_name>Fusheng Wang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>January 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2012</study_first_posted>
  <last_update_submitted>January 8, 2012</last_update_submitted>
  <last_update_submitted_qc>January 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyponatremia</keyword>
  <keyword>Non-hypovolemic and Non-acute hyponatremia</keyword>
  <keyword>Tolvaptan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

